Hepatitis Monthly

Published by: Kowsar

Entecavir Versus Lamivudine Therapy for Patients With Chronic Hepatitis B-Associated Liver Failure: A Meta-Analysis

Xiaoguo Zhang 1 , Yong An 2 , Xuemei Jiang 1 , Minling Xu 1 , Linlin Xu 1 , Shijun Chen 1 , * and Yaguang Xi 3
Authors Information
1 Division of Liver Disease, Jinan Infectious Disease Hospital, Shandong University, Jinan, China
2 Division of Liver Disease, Qianfoshan Hospital, Shandong University, Jinan, China
3 Mitchell Cancer Institute, University of South Alabama, Mobile, USA
Article information
  • Hepatitis Monthly: November 01, 2014, 14 (11); e19164
  • Published Online: November 11, 2014
  • Article Type: Research Article
  • Received: March 28, 2014
  • Revised: September 17, 2014
  • Accepted: October 12, 2014
  • DOI: 10.5812/hepatmon.19164

To Cite: Zhang X, An Y, Jiang X, Xu M, Xu L, et al. Entecavir Versus Lamivudine Therapy for Patients With Chronic Hepatitis B-Associated Liver Failure: A Meta-Analysis, Hepat Mon. 2014 ;14(11):e19164. doi: 10.5812/hepatmon.19164.

Abstract
Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Zhang C, Zhong Y, Guo L. Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices. Biosci Trends. 2013; 7(1): 7-12[PubMed]
  • 2. Chinese Society of H, Chinese Society of Infectious Diseases CMA. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(1): 13-24[DOI][PubMed]
  • 3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
  • 4. Organization Committee of 13th Asia-Pacific Congress of Clinical M. 13th Asia-Pacific Congress of Clinical Microbiology and Infection Consensus Guidelines for diagnosis and treatment of liver failure. Hepatobiliary Pancreat Dis Int. 2013; 12(4): 346-54[PubMed]
  • 5. Guidelines for diagnosis and treatment of liver failure. Chin J Clin Infect Dis. 2012; 5(6): 321-7
  • 6. Diagnostic and treatment guidelines for liver failure Chin J Hepatol 2006; 14(9): 643-6
  • 7. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009; 3(1): 269-82[DOI][PubMed]
  • 8. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012; 55(3): 965-7[DOI][PubMed]
  • 9. Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012; 32(4): 544-53[DOI][PubMed]
  • 10. Huo L. Effect of entecavir in patients with chronic severe hepatitis B. J Xinxiang Med Coll. 2008; 25(5): 482-4
  • 11. Lei F. The treatment effect of enticavir on chronic severe hepatitis B. Med Front. 2013; 8: 7-8
  • 12. Lai J, Yan Y, Mai L, Zheng YB, Gan WQ, Ke WM. Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure. Hepatobiliary Pancreat Dis Int. 2013; 12(2): 154-9[PubMed]
  • 13. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009; 50(6): 2001-6[DOI][PubMed]
  • 14. Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol. 2011; 54(2): 236-42[DOI][PubMed]
  • 15. National viral hepatitis control programme. Chin J hepatol. 2000; 8(6): 324-9
  • 16. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014;
  • 17. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2): 455-63[PubMed]
  • 18. Hu JH, Wang HF, He WP, Liu XY, Du N, Huang K, et al. [Lamivudine and entecavir significantly improved the prognosis of early-to-mid stage hepatitis B related acute on chronic liver failure]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010; 24(3): 205-8[PubMed]
  • 19. Zhiyong Y, Dongxia L, Ni W. Observation of efficacy and safety of entecavir in treatment of liver failure. Mod Chin Dr. 2012; 50(14): 71-4
  • 20. Wang X. The effects of entecavir and lamivudine for patients with chronic severe hepatits b. Chin Mod Med. 20; 17(34): 62-6
  • 21. Fang L, Chen T, Jiangxia D. The short-term clinical effect of entecavir in the treatment of patients with chronic severe hepatitis B. J Clin Hepatol . 2008; 11(6): 383-4
  • 22. Xu QH, Chen LB, Xu Z, Shu X, Chen N, Cao H, et al. [The short-term efficacy of antiviral treatment in patients with acute-on-chronic hepatitis B liver failure]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009; 23(6): 467-9[PubMed]
  • 23. Cuijun P, Wenqiu L, Ying Z. Entecavir for chronic severe viral hepatitis B: clinical observation of 45 cases. Progress in Modern Biomedicine. Prog Mod Biomed. 2010; 10(24): 4735-7
  • 24. Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010; 55(8): 2373-80[DOI][PubMed]
  • 25. Hongbo G, Min X, Haiyan S, Yueping L, Lei X. Clinical analysis of antiviral treatment in chronic severe hepatitis B with HBVDNA positive. Chin J Integr Tradit West Med Liver Dis. 2011; 21(6): 330-2
  • 26. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, et al. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med. 2012; 12(3): 159-64[DOI][PubMed]
  • 27. Wang J, Ma K, Han M, Guo W, Huang J, Yang D. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: Validation of the TPPM model. Hepatol Int. 2014; 8(1): 64-71[DOI]
  • 28. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000; 32(4 Pt 1): 734-9[DOI][PubMed]
  • 29. Wang J, Jiang D, Zhang H, Lv S, Rao H, Fei R, et al. Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2. Proteomics. 2009; 9(6): 1672-82[DOI][PubMed]
  • 30. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45(4): 1056-75[DOI][PubMed]
  • 31. Zhao Z, Han T, Gao Y, Gao Y, Zhang Y, Wu Z. Analysis on the predisposing cause and outcome of 289 cases of hepatitis B patients complicated with chronic or acute liver failure. World J Gastroenterol . 2009; 17: 3269-72
  • 32. Ma K, Guo W, Han M, Chen G, Chen T, Wu Z. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: Establishment of a novel logistical regression model. Hepatol Int. 2012; 6(4): 735-43[DOI]
  • 33. Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int. 2013; 7(2): 460-7[DOI]
  • 34. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol. 2010; 25(3): 583-90[DOI][PubMed]
  • 35. Sun QF, Lu Y, Xu DZ, Lan XY, Liu JY, Sun XJ. The impact of HBeAg positivity/negativity and HBV DNA loads on the prognosis of chronic severe hepatitis B. Chin J Hepatol. 2006; 14(6): 410-3
  • 36. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354(10): 1011-20[DOI][PubMed]
  • 37. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10): 1001-10[DOI][PubMed]
  • 38. Hsu YC, Mo LR, Chang CY, Perng DS, Tseng CH, Lo GH, et al. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. Antivir Ther. 2012; 17(4): 605-12[DOI][PubMed]
  • 39. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011; 53(1): 62-72[DOI][PubMed]
  • 40. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011; 54(1): 91-100[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments